Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - clarithromycinum inn - filmuhúðuð tafla - 500 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - kyrningahvítblæði, mergbólga - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig - bosutinib (sem einhýdrat) - kyrningahvítblæði, mergbólga - antineoplastic agents, protein kinase inhibitors - bosulif er ætlað fyrir meðferð fullorðinn sjúklinga með:nýlega‑greind langvarandi áfanga (aÐili) philadelphia litning-jákvæð langvarandi myelogenous hvítblæði (ph+ cml). aÐili, flýta áfanga (ap), og sprengja áfanga (bp) ph+ cml áður meðhöndluð með einn eða fleiri týrósín nt hemil(s) [tki(s)] og fyrir hvern imatinib, nilotinib og dasatinib eru ekki talin viðeigandi meðferð valkosti.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 og 5.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacín hýdróklóríð - attention deficit disorder með ofvirkni - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv verður að vera notað sem hluti af alhliða kynlÍf meðferð áætlun, venjulega þar á meðal sálfræðilega, mennta og félagslega mælist.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - krabbamein, lungnakrabbamein - Önnur antineoplastic lyf, prótín nt-hemlar - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - kyrningahvítblæði, mergbólga, bráð - Æxlishemjandi lyf - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

mylan ire healthcare limited - pretomanid - berklar, fjölþol-þolir - antimycobacterials - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - Ónæmisbælandi lyf - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirus sýkingar - veirueyðandi lyf til almennrar notkunar - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). Íhuga ætti að opinbera leiðsögn á réttri notkun af veirum.